19:55 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Cell culture and mouse studies suggest GHRH receptor agonists could help treat heart failure. In a rat cardiomyoblast cell line, primary rat ventricular myocytes and human induced pluripotent stem (iPS) cell-derived cardiomyocyte...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

Theratechnologies, BL&H deal

Theratechnologies granted BL&H rights to develop and commercialize Egrifta tesamorelin in South Korea to treat HIV-associated lipodystrophy. BL&H is responsible for registration in the territory and will distribute the analog of growth hormone-releasing factor through...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Telesta, BL&H deal

Telesta granted BL&H exclusive rights to commercialize MCNA in South Korea. In June, Telesta submitted a BLA to FDA for the mycobacterial cell wall-DNA complex (MCC) to treat high-risk non-muscle invasive bladder cancer in patients...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Financial News

Telesta completes private placement

Telesta Therapeutics Inc. (TSX:TST; Pink:BNHLF), Belleville, Ontario   Business: Cancer   Date completed: 2015-07-20   Type: Private placement   Raised: $200,000   Price: C$0.33   Shares after offering: 171.6 million   Investor: BL&H Co. Ltd....
07:00 , May 14, 2012 |  BC Week In Review  |  Company News

BL&H, Clinigen Group, Hospira, AstraZeneca sales and marketing update

Clinigen's Clinigen Healthcare division granted BL&H exclusive rights to commercialize Foscavir foscarnet in South Korea. The companies will collaborate on regulatory approval for the product to treat herpes, cytomegalovirus (CMV) infection and CMV in hematopoietic...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Company News

BL&H, Cardium sales and marketing update

Cardium granted BL&H Korean commercialization rights to Excellagen . Cardium will manufacture and supply the topical collagen-based gel matrix while BL&H will be responsible for regulatory approval. Terms were not disclosed. FDA approved the product...
07:00 , Sep 22, 2008 |  BC Week In Review  |  Company News

Alfacell cancer news

Alfacell retained Oppenheimer & Co. to explore strategic alternatives, including partnerships or a possible sale of the company. Alfacell's lead candidate is Onconase ranpirnase. The company expects to complete a rolling NDA for Onconase to...
08:00 , Feb 25, 2008 |  BC Week In Review  |  Company News

Dor BioPharma, BL&H Co. Ltd. sales and marketing update

The companies signed a letter of intent for BL&H to distribute Dor's orBec beclomethasone dipropionate to treat acute gastrointestinal graft-versus-host disease (GvHD) as part of the Korea Orphan Drug Center's (KODC) compassionate use program. The...
08:00 , Jan 28, 2008 |  BC Week In Review  |  Company News

Alfacell, BL&H Co. Ltd. sales and marketing update

BL&H received exclusive rights to market, sell and distribute Onconase ranpirnase in South Korea, Taiwan and Hong Kong. Alfacell received $100,000 up front and is eligible for milestones and 50% of net sales. Onconase is...
08:00 , Jan 21, 2008 |  BC Week In Review  |  Clinical News

Aridol mannitol regulatory update

Pharmaxis was granted South Korean marketing approval for its Aridol mannitol asthma test. The dry powder inhalation test is administered to the lungs through an inhaler to measure the severity of asthma and the effectiveness...